Quantitative Transmission Imaging Compared with MRI as Supplemental Screening in Patients with High Lifetime Risk of Breast Cancer

This clinical trial compares the use of quantitative transmission imaging (QTI) to standard of care MRI as a supplemental screening tool for patients with a high lifetime risk of breast cancer. QTI is a single 3D ultrasound test intended to be used as an initial evaluation method for asymptomatic women identified with above-average risk for developing breast cancer. Using QTI may be an effective supplemental screening tool, compared to MRI for patients with a high lifetime risk of breast cancer.

Additional locations may be listed on ClinicalTrials.gov for NCT07216274.

See trial information on ClinicalTrials.gov for a list of participating sites.

Trial PhaseNo phase specified

Trial Typescreening

Lead OrganizationMayo Clinic in Rochester

Principal InvestigatorTiffany M. Sae-Kho

• Primary ID24-008575
• Secondary IDsNCI-2025-07168
• ClinicalTrials.gov IDNCT07216274